A new study published in the July 2006 Archives of Ophthalmology suggests that intake of fatty acids found in fish may help prevent age-related maculopathy, a deterioration of the eye's retina that can lead to blindness.

The new study runs contrary to several other studies in recent years that have found a link between high fat intake - from any source - and a higher risk of age-related maculopathy (ARM), the leading cause of vision loss among the elderly

Cigarette smoking increases the risk of the most common cause of blindness among the elderly but eating fish protects against it, according to CNN.

A study from the Massachusetts Eye and Ear Infirmary in Boston found that those who smoked had nearly a two fold-increased risk of age-related macular degeneration compared to those who had never smoked.

There was also a higher risk for those who had smoked in the past but quit

According to a new study, the tiniest premature infants fed with breast milk in the hospital do better on tests of mental development later in life than others fed only on formula.

The study, which is the first of its kind, shows the benefits of breast milk for babies born weighing less than 2 pounds, 3 ounces.

With medical advances, hospitals are saving more of these babies, some born more than three months early

Even when blood alcohol levels are half the legal driving limit, people tend to miss objects that appear suddenly in their field of vision, reports a study done by researchers at the University of Washington.

The phenomenon, which is commonly called intentional blindness, happens in people who are sober as well. Dr. Seema L.Clifasefi observes that alcohol has been known to impair motor skills, reaction time and visual attention. However, until now no one has looked into the effects of alcohol on intentional blindness

The Food and Drug Administration approves Lucentis for the treatment of patients with neovascular (wet) age-related macular degeneration. Lucentis is the first treatment which can maintain the vision of more than 90 percent of patients with this type of AMD.

The FDA says Lucentis is a new molecular entity, meaning it contains an active substance that has never before been approved for marketing in any form in the U.S. Lucentis will be the first FDA-approved product to provide prescription information in the new format for prescription drug package inserts. These are designed to provide professionals and consumers clear and concise prescription information